Neutral Endopeptidase Activity is Increased in the Skin of Subjects with Diabetic Ulcers  by Antezana, Marcos A. et al.
ORIGINAL ARTICLE
Neutral Endopeptidase Activity is Increased in the
Skin of Subjects with Diabetic Ulcers
Marcos A. Antezana, Stephen R. Sullivan, Marcia L. Usui, Nicole S. Gibran,n Michelle L. Spenny,n
Jerrie A. Larsen,w John C. Ansel,z NigelW. Bunnett,y and John E. Olerud
Departments of Medicine (Dermatology) and nSurgery, University of Washington, Seattle,WA, U.S.A.; wDepartment of Orthopaedics,Veterans A¡airs
Puget Sound Health Care System, Seattle,WA, U.S.A.; zDepartment of Dermatology, Emory University, Atlanta, GA, U.S.A.; yDepartments of Physiology
and Surgery, UCSF, San Francisco, CA, U.S.A.
Cutaneous sensory nerves mediate in£ammation and
wound healing by releasing neuropeptides, such as sub-
stance P, which stimulates pro-in£ammatory responses
by keratinocytes, ¢broblasts, and endothelial cells. The
cell surface enzyme, neutral endopeptidase, degrades
substance P, thereby regulating its biologic actions.We
hypothesized that neutral endopeptidase enzymatic ac-
tivity is increased in chronic wounds and skin from
subjects with diabetes.We compared cutaneous neutral
endopeptidase expression and enzymatic activity be-
tween normal controls and diabetic subjects with neu-
ropathy and chronic wounds. Skin samples from
subjects with diabetes were taken at the time of ampu-
tation for nonhealing ulcers. Skin taken from the ulcer
margin, 1 cm from the ulcer (adjacent), and from
the most proximal region of the amputated leg were
studied. Skin biopsies from the leg of healthy control
subjects were also studied. Neutral endopeptidase was
localized by immunohistochemistry in all tissue sec-
tions. Neutral endopeptidase activity was measured
using a £uorimetric assay. The median neutral endo-
peptidase activity of the ulcer margin was 1.21higher
(p40.2) than adjacent skin, 5.26higher (po0.001) than
proximal skin, and 15.22higher (po0.001) than con-
trol skin. Adjacent skin had a median neutral endopep-
tidase activity 4.34higher (po0.001) than proximal
skin and 12.58higher (po0.001) than control skin.
The median neutral endopeptidase activity of proximal
skin was 2.90higher (po0.001) than control skin. This
elevated neutral endopeptidase activity in the skin and
chronic ulcers of subjects with diabetes combined with
peripheral neuropathy may contribute to de¢cient neu-
roin£ammatory signaling and may impair wound heal-
ing in subjects with diabetes. Key words: in£ammation/
nerves/neuropeptides/substanceP/wound healing. J Invest
Dermatol 119:1400 ^1404, 2002
T
he cutaneous sensory nervous system carries a¡erent
signals originating in the periphery towards the cen-
tral nervous system for interpretation of pain, pres-
sure, and thermal stimuli. Sensory nerves extend
into the epidermis as ¢nely branching ¢laments that
appear to originate from either small dermal nerve bundles
(Hilliges et al, 1995) or a single dermal trunk (Reilly et al, 1997).
These nerve ¢bers are noted by light (Hilliges et al, 1995), electron
(Hilliges et al, 1995), and confocal microscopy (Reilly et al, 1997)
to be distributed throughout the basal, spinous, and granular
layers of the epidermis and make close contact with keratinocytes
via membrane^membrane apposition. Nerve ¢bers also appear to
contact Langerhans cells (Hosoi et al, 1993) and human dermal
microvascular endothelial cells (Ansel et al, 1997). Many epidermal
and dermal sensory nerves stain positively for substance P (SP)
(Levy et al, 1989; Lindberger et al, 1989; Schulze et al, 1997). The
presence of SP in free nerve ¢ber endings and the proximity of
these endings to a variety of cells in the skin seems to implicate
the cutaneous sensory nervous system not merely for its role in
sensation but in other biologic actions as well (Ansel et al, 1996).
Neuropeptide involvement in cutaneous in£ammation has
been extensively demonstrated (Payan, 1989). By means of its ac-
tions on the vasculature, cutaneous epithelium, and connective
tissue, SP may mediate events involved in cutaneous in£amma-
tion and wound healing (Ansel et al, 1996). Through both direct
action on endothelial cells and stimulation of increased nitric
oxide release, SP stimulates vasodilatation and microvascular per-
meability (Khalil and Helme, 1989; Baraniuk et al, 1990). Expres-
sion of adhesion molecules on endothelial cells (Quinlan et al,
1998, 1999; Lindsey et al, 2000), monocyte chemotaxis (Helme et
al, 1987), and in£ammatory cell activity (Lambert and Granstein,
1998) are all upregulated by SP. SP stimulates neutrophil and mast
cell activity directly and induces human-dermal microvascular
endothelial cells to produce interleukin-8 (Kramp et al, 1995). SP
also stimulates DNA synthesis (Tanaka et al, 1988) and prolifera-
tion (Tanaka et al, 1988; Paus et al, 1995) by keratinocytes, and
DNA synthesis by ¢broblasts (Nilsson et al, 1985) as well as stimu-
lating proliferation by endothelial cells and inducing neovascular-
ization (Ziche et al, 1990).
The e¡ects of SP are mediated primarily through a neurokinin
receptor, NK-1R, a G-protein coupled receptor expressed in ner-
vous and peripheral tissues. NK-1R mRNA can be found in ker-
atinocytes, ¢broblasts, dermal endothelial cells, and circulating
immune cells (Scholzen et al, 1998). The major regulatory
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mechanism of SP is enzymatic degradation. A zinc metallopro-
tease known as neutral endopeptidase (NEP) is anchored, by a
small hydrophobic amino acid chain with its active site facing
the extracellular space (Roques et al, 1993), and is present in the
cell membrane of the same cells that express NK-1R. NEP com-
petes with NK-1R and hydrolyzes peptide bonds on the amino
terminal end of hydrophobic substrates such as SP (Roques et al,
1993). Enzymatic degradation of SP requires high concentration
and coexpression of NEP with NK-1R (Okamoto et al, 1994).
NEP expression is immunolocalized to keratinocytes, dermal
appendages, and the microvasculature of the skin (Olerud et al,
1999), and is found on cultured skin ¢broblasts (Bou-Gharios
et al, 1995). Fluorimetric assays con¢rm NEP enzymatic activity
in the skin of mice (Paus et al, 1994) and guinea pigs (Iwamoto
et al, 1989). NEP inhibitors increase SP-induced plasma extravasa-
tion (Iwamoto et al, 1989), and NEP knockout mice exhibit spon-
taneous plasma extravasation and cutaneous edema (Ansel et al,
1996; Scholzen et al, 2001). Synthesis and secretion of SP, interac-
tion of SP with the SP receptor on the cell membrane and degra-
dation of SP by NEP are key elements of neuroin£ammatory
signaling in wound repair (Ansel et al, 1996).
In normal unwounded skin, NEP is immunolocalized to the
cell membranes of basal keratinocytes (Olerud et al, 1999); how-
ever, the NEP staining pattern in standardized human incisional
wounds (Olerud et al, 1995) extends to cover the wound matrix,
full thickness of the epidermis, and to a ‘‘transitional’’ zone 30^50
cells lateral to the wound margin by 7 d postwounding (Olerud
et al, 1999). Increased NEP mRNAwas also demonstrated in nor-
mal 3 d and 7 d wounds by northern blot analysis. Immunoloca-
lization of NEP returns to normal basal cell staining by 28 d
postwounding (Olerud et al, 1999).
Chronic, nonhealing foot ulcers are a signi¢cant problem for
subjects with diabetes, accounting for one-quarter of the days
spent in the hospital by this population (Bild et al, 1989). Evidence
shows that there is a disruption in neural signaling pathways,
which is important for wound healing in subjects with diabetes.
Subjects with diabetes with both neuropathy and signi¢cant per-
ipheral vascular disease show no evidence of SP immunoreactive
nerves in the skin (Levy et al, 1989). The purpose of this study was
to compare cutaneous NEP expression and enzymatic activity in
the lower extremities of diabetic subjects with normal controls.
Skin samples from various locations on the lower extremity of
subjects with diabetes were also studied, including the margin of
chronic ulcers, unwounded adjacent skin as well as proximal leg
skin.
MATERIALS AND METHODS
Tissue collection Eight subjects with diabetes undergoing lower
extremity amputation at the Veterans A¡airs Puget Sound Health Care
System were recruited. Ten age-matched healthy control subjects were
recruited by an advertisement in a daily newspaper. Informed consent was
obtained from all subjects in accordance with procedures approved by the
University of Washington Institutional Review Board for Research on
Humans. The normal volunteers were screened and excluded if they had a
history of cardiovascular disease, hypertension, diabetes mellitus, smoking
in the past 10 y, or alcoholism.To con¢rm that the subjects had no evidence
of diabetes mellitus, peripheral vascular disease, or neuropathy, a physical
examination, including testing for light touch (Semmes^Weinstein
¢lament) and vibration sensation, and a laboratory examination, including
fasting blood glucose and hemoglobin A1c levels, were carried out.
Skin samples from diabetic subjects were harvested in the operating
room immediately following amputation. Samples were collected from:
(i) the ulcer margin; (ii) unwounded skin free of in£ammation 1cm away
from the ulcer margin (adjacent skin); and (iii) unwounded skin from the
most proximal part of the amputated lower extremity (proximal skin).
Unwounded skin samples from control subjects (control skin) were
removed 10 cm distal to the patella from a region on the lateral leg
comparable with where the proximal sample taken from the diabetic
subjects. Samples were taken from control subjects using a 6mm skin
biopsy punch after local anesthesia with 1^2ml of 1% lidocaine with
epinephrine. Samples were trimmed of subcutaneous fat, and frozen as
quickly as possible (usually within 1^2min of excision) in OCT (Sakura
Finetek, Torrance, CA) for immunohistochemistry or on a block of dry
ice for NEP enzymatic assays. All skin was stored at ^701C.
Immunohistochemistry Six micron frozen tissue sections were
immunolabeled using standard ABC methods as previously published
(Olerud et al, 1999). Brie£y, slides were post¢xed in 4% paraformaldehyde
and incubated with NEP anti-serum at 1: 200 dilutions. Biotinylated goat
anti-rabbit antibody (Vector Laboratories, Burlington, CA) at 1: 200
dilution was used as a secondary antibody followed by streptavidin^biotin
complex (SABC Universal Kit, Zymed Laboratories, San Francisco, CA) at
1: 200 dilution. 3,30 diaminobenzidine (Sigma, St Louis, MO) was used as
chromogen, control slides were incubated without.
Tissue preparation for NEP enzymatic assay Frozen skin samples
were weighed and kept on ice throughout preparation for the enzymatic
assay. Skin was placed in a small amount of 50mmol per l. Tris^HCl, pH
7.5, and cut into smaller pieces using a sterile razor blade. To minimize
protein degradation during tissue preparation, 1mmol per l
phenylmethylsulfonyl £uoride (Sigma) and 1 mmol per l Pepstatin A
(Peninsula Laboratories, Inc., Belmont, CA) were used. Skin samples were
homogenized for 1min using a Tissue Mizer (Sakura Finetek, Torrance,
CA) followed by manual homogenization using a ground-glass
homogenizer. Samples were then aliquoted and stored at ^701C. This
method was adapted from that previously described by Terashima et al
(1992).
Determination of protein concentration Protein concentration was
measured using Bradford dye reagent (Bio-Rad Laboratories, Richmond,
CA) (Bradford, 1976). Twenty microliter aliquots of sample homogenate
were thawed, diluted with 20 ml of 1M NaOH, dissolved at room
temperature for 30min and centrifuged at 14,000 g for 2min. The
supernatant was diluted 1:10 in 50mmol per l Tris^HCl, pH 7.5. Twenty
microliters of the diluted supernatant was added to 780 ml of distilled
water. Two hundred microliters of dye reagent was added to the 800 ml of
diluted sample, mixed gently and allowed to sit for 5min. Absorption was
read at 595 nm (Beckman DU-50, Beckman Coulter, Inc., Fullerton, CA).
Skin samples were run in triplicate and spectrophotometric readings were
averaged. The protein concentration (mg per ml) of each homogenate was
then determined by comparison with a BSA (bovine serum albumin)
standard curve.
Fluorimetric assay NEP activity (pmol 4-Methoxy-2-napthylamine
MNA per h per mg) of tissue homogenates was assayed £uorimetrically
using a previously described method (Erdos et al, 1989; Terashima et al,
1992; Bunnett et al, 1993; Hwang et al, 1993). Aliquots of sample
homogenates were thawed and 50 mg of protein, as determined by
spectrophotometry, was used per reaction. The homogenates were
incubated at 371C for 10min in 50mmol per l Tris^HCl, pH 7.5
containing 4 mg aminopeptidase M per ml (Calbiochem, San Diego, CA).
These homogenates were then incubated with or without 25mmol per l
DL-thiorphan (Sigma), an inhibitor speci¢c to NEP activity. To each
sample, 40mmol per l glutaryl-Ala-Ala-Phe-4-methoxy-2-naphthylamine
was added (Enzyme Systems Products, Livermore, CA) and incubated at
371C for 30min. Samples were centrifuged at 14,000 g for 2min. Two
hundred microliters of supernatant was added to 1.8ml of 1.1M
dithiothreitol (Sigma) to stop the reaction. Fluorescence of the samples
was measured using a £uorometer (Shimadzu, Scienti¢c Instruments, Inc.,
Columbia, MD) with excitation wavelength of 340 nm and emission
wavelength of 425 nm. Skin samples were run in triplicate and £uorescent
readings were averaged. The amount of £uorescent product generated by
NEP activity was determined by subtracting the arbitrary £uorescence
units produced by samples incubated with DL-thiorphan from the
arbitrary £uorescence units produced by samples incubated without DL-
thiorphan. Only activity that was inhibited by DL-thiorphan was
attributed to NEP. Arbitrary £uorescence units of each sample were
compared with an MNA (Sigma) standard curve. NEP enzymatic activity
was then expressed as pmol of MNA per h per mg of total protein.
Statistical analysis To examine potential di¡erences in protein
concentration and cutaneous NEP activity among the skin samples, a
regression analysis with indicator variables for the site of biopsy was
performed using Stata 6.0 software (StataCorp, College Station,TX 1999).
A logarithmic transformation of NEP activity was used to adjust for
heteroscedasticity in the distribution of the data. Results, expressed as
mean 7 SD and 95% con¢dence intervals (CI), were corrected for
multiple comparisons using Bonferroni’s method (Kleinbaum et al, 1998).
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RESULTS
All eight diabetic subjects were males undergoing lower extre-
mity amputation. The fact that all subjects were males re£ected
theVeterans Administration Hospital population with diabetic ul-
cers requiring amputation during the study period. Age of pa-
tients ranged from 66 to 79 y (mean¼ 68.7). All patients were
insulin dependent at the time of their operation and hemoglobin
A1c levels varied from 6.1 to 12.1% (mean¼ 8.25%). The normal
range for hemoglobin A1c is 4.4^6.4%. Neurologic testing re-
vealed an inability to detect a 5.07 Semmes^Weinstein ¢lament
consistent with severe diabetic neuropathy in the feet of all but
one subject tested.
Control subjects included seven males and three females with
ages that ranged from 52 to 79 y (mean¼ 65.7). History and phy-
sical examination established that all normal volunteers were free
of clinically apparent cardiovascular disease, peripheral neuropa-
thy, or diabetes mellitus. All control subjects had a normal fasting
blood glucose that varied from 83 to 108 (mean¼ 93) at the time
of biopsy and had been previously shown to have normal hemo-
globin A1c levels that varied from 4.9 to 6.8% (mean¼ 5.7%).
Neurologic testing with the Semmes^Weinstein ¢lament and
tuning fork revealed normal sensation in the feet of all control
subjects. None of the control subjects had wounds on the lower
extremities.
A total of eight ulcer margins, eight adjacent skin, and six
proximal skin samples were taken from diabetic subjects. Two
subjects with diabetes had ankle disarticulations rather than
below knee amputations, hence no proximal skin specimen
was available. Ten control skin specimens were harvested.
Immunohistochemistry showed increased NEP in ulcer mar-
gin and adjacent skin of diabetic subjects. NEP was immunolo-
calized to basal keratinocytes in control skin (Fig. 1A), whereas
NEP was dramatically increased throughout epidermal and der-
mal layers of ulcer margin (Fig. 1B) and adjacent skin (Fig. 1C),
and variable in the proximal skin (Fig. 1D,E) of subjects with
diabetes. NEP immunostaining of proximal skin was, however,
more extensive than control skin. For the most part, immunos-
taining of NEP was both cytoplasmic and membranous. NEP
also appeared to stain extracellular matrix in ulcer margin and
adjacent skin samples (Fig 1B, asterisk). Immunohistochemistry
without primary antibodies showed no staining (data not shown).
Protein concentration of the skin samples was determined.
Protein content of the ulcer margin was 3.85 7 0.88mg per ml,
adjacent skin was 1.9870.69 mg per ml, proximal skin was
1.0870.78 mg per ml, and normal control skin was 0.7970.20 mg
per ml. The statistically signi¢cant di¡erences in protein concen-
tration in these skin samples were as follows: the ulcer margin
had signi¢cantly greater protein concentration than all other skin
samples (po0.05), adjacent skin was signi¢cantly higher in pro-
tein concentration than control skin (po0.05), and no other dif-
ferences in protein concentrations of the skin samples were
statistically signi¢cant.
The NEP enzymatic assay showed the highest cutaneous NEP
activity to be in ulcer margin samples (Fig. 2). The cutaneous
NEP activity of the ulcer margin was 47.54717.18 pmol MNA
per h per mg. NEP activity in adjacent skin was 41.44720.48
pmol MNA per h per mg. Proximal skin showed considerably less
cutaneous NEP activity than both ulcer margin and adjacent
skin with 9.0673.60 pmol MNA per h per mg. In control skin,
cutaneous NEP activity was 3.4271.84 pmol MNA per h per
Figure1. NEP immunohistochemistry of normal and diabetic skin.
(A) Normal, unwounded skin with large arrow indicating NEP staining of
basal keratinocytes and small arrows showing NEP staining of blood vessels.
(B) Ulcer margin from a patient with diabetes with asterisk (n) indicating
ulcer bed. Note strong NEP staining throughout the epidermis and strong
dermal matrix staining. (C) Unwounded skin adjacent to the ulcer from a
subject with diabetes showing strong NEP staining throughout the epider-
mis. (D,E) Unwounded skin from the proximal regions from two di¡erent
patients with diabetes showing variability of NEP epidermal staining
where D shows strong epidermal staining and E shows a staining pattern
approaching that of normal skin. Scale bar¼ 50 mm
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mg. Analysis of NEP activity in controls showed no signi¢cant
di¡erences between male and female subjects.When female sub-
jects were removed from the analysis, cutaneous NEP activity for
control men was 3.6171.90 pmol MNA per h per mg.
When the median cutaneous NEP activity level of the ulcer
margin was compared with the median cutaneous NEP activity
level for adjacent skin samples 1cm from the ulcer, the ulcer mar-
gin was found to be 1.21 times higher (95% CI: 1.70^2.49 times
higher).This di¡erence, however, was not greater than that which
could be explained by random sampling error in the absence of a
true di¡erence with respect to the e¡ect of site of skin biopsy
(p40.2). The median cutaneous NEP activity of the ulcer margin
was 5.26 times higher than the activity level of proximal skin
from those same patients (95% CI: 2.42^11.45 times higher,
po0.001) and 15.22 times higher than control skin (95% CI:
7.68^30.15 times higher, po0.001) (Table I).
When the median cutaneous NEP activity level of adjacent
skin in subjects with diabetes was compared with the proximal
skin samples from those same patients, the adjacent skin
was found to be 4.34 times higher than the proximal skin (95%
CI: 1.99^9.46 times higher, po0.001). The median cutaneous
NEP activity level for adjacent skin in subjects with diabetes was
estimated to be 12.58 times higher (95% CI: 6.35^24.92 times
higher, po0.001) than control skin. The median cutaneous
NEP activity level of the proximal skin was estimated to be 2.90
times higher (95% CI: 1.38^6.10 times higher, po0.001) than
control skin (Table I).
DISCUSSION
This study documents high levels of NEP enzymatic activity in
the skin and high immunoreactivity in the epidermis and dermis
of the ulcer margin and adjacent skin of subjects with diabetes
compared with normal control subjects. Likewise, median cuta-
neous NEP activity levels are signi¢cantly increased in un-
wounded skin of subjects with diabetes compared with skin
samples taken from normal control subjects at a comparable loca-
tion on the lateral leg. Progressively and signi¢cantly higher le-
vels of cutaneous NEP activity were observed in the skin of
subjects with diabetes with values for NEP increasing from prox-
imal to distal, with the ulcer margins having the highest values.
The cutaneous NEP activity of the adjacent skin samples tended
to be lower than the samples from the ulcer margins but this dif-
ference was not statistically signi¢cant. These adjacent samples
were removed from areas of intact skin without clinically signi¢-
cant in£ammation. Hence, we may not conclude from these ex-
periments that chronic ulcers in subjects with diabetes have
greater NEP activity than unwounded adjacent skin even though
both areas were more than 10-fold higher than skin from normal
control subjects.We did not biopsy the legs and feet of diabetic
subjects without leg ulcers to evaluate the e¡ect of diabetes alone
on NEP expression in the skin. We were concerned that such
biopsies by themselves could result in nonhealing wounds. We
have, however, observed in diabetic db/db mice that the cuta-
neous NEP enzymatic activity in unwounded skin is 2^3
(p¼ 0.02) that of control nondiabetic littermates (Spenny, 2002).
Unwounded skin from the proximal leg of diabetic subjects,
however, has much lower NEP activity levels than the more distal
sites. One could speculate that these di¡erences in NEP activity
between the proximal and distal leg may account for the im-
paired neuroin£ammatory signaling and poor healing of these
chronic ulcers. The di¡erences in healing may also be due to re-
gional variation in a variety of other factors, including decreased
innervation, decreased skin perfusion, and increased likelihood of
trauma. If these di¡erences are due to regional variation, it is in-
teresting to note that higher NEP activity occurs in a region most
prone to developing neuropathy and chronic ulcers. Clearly, neu-
ropathy leads to decreased release of neuropeptides.Whereas fac-
tors regulating the production of NEP in the skin have not been
de¢ned, it is tempting to speculate that somehow the decrease in
neuropeptides may be linked to an increase in the production of
NEP. It is not known whether the high levels of NEP in the ad-
jacent skin and ulcers of subjects with diabetes proceeds or fol-
lows the development of chronic wounds. Previous studies in
normal subjects demonstrated an increase in wound NEP during
the ¢rst week following an acute wound. Thereafter, the NEP
immunostaining returned to a pattern and intensity of staining
resembling the prewounded state (Olerud et al, 1999).The increase
and subsequent decrease in NEP after wounding is presumably a
mechanism for downregulation of the neuroin£ammatory signal-
ing pathways activated during the normal healing response. As
NEP degrades SP, a mediator of neuroin£ammatory signaling
for the repair response in keratinocytes, ¢broblasts, endothelial
cells, and in£ammatory cells (reviewed in Olerud et al, 1999), it
follows that the high level of NEP observed in the skin of pa-
tients with diabetic ulcers could lead to diminished or absent
neuroin£ammatory signaling and impaired wound healing.
Homogenates of ulcer margin samples have a signi¢cantly
higher protein concentration than adjacent and proximal homo-
genates. Given the presence of a signi¢cant amount of exudate in
the ulcers, the percentage of protein in the ulcer margin homo-
genates attributable to NEP may actually be decreased relative to
that found in adjacent and proximal homogenates. As NEP activ-
ity is expressed in terms of total protein used in the reaction, the
NEP activity in the viable tissue of the ulcer margin may there-
fore be even higher than what was reported in this study.
NEP activity was measured in homogenates of full thickness
excisional skin biopsies from subjects with diabetes.Whereas the
results from this study do not determine which cells in the skin
were the source of high levels of NEP, the immunohistochemis-
try studies showed staining throughout all layers of the epidermis
and dermis, suggesting that keratinocyte, ¢broblast, and endothe-
lial cell NEP expression is increased and may be the source of
high NEP activity. Fibroblasts, endothelial cells, and other cells
have been previously shown to express NEP (Ansel et al, 1996;
Olerud et al, 1999).
Figure 2. Cutaneous NEP activity (pmol MNA per h per lg) of skin
homogenates determined with £uorimetric assay. For each skin sam-
ple, three £uorimetric readings were averaged and compared with a stan-
dard curve to determine NEP activity. Results are mean7SD.
Table I. Regression analysis comparing NEP activity with
skin sample location
Median
di¡erence in
Skin sample comparisons NEPActivity p-valuea 95% CI
Ulcer margin (U)/Adjacent skin (A) 1.21 (U/A) 4 0.2 (1.70^2.49)
Ulcer margin (U)/Proximal skin (P) 5.26 (U/P) o 0.001 (2.42^11.45)
Ulcer margin (U)/Control skin (C) 15.22 (U/C) o 0.001 (7.68^30.15)
Adjacent skin (A)/Proximal skin (P) 4.34 (A/P) o 0.001 (1.99^9.46)
Adjacent skin (A)/Control skin (C) 12.58 (A/C) o 0.001 (6.35^24.92)
Proximal skin (P)/Control skin (C) 2.90 (P/C) o 0.001 (1.38^6.10)
aAdjusted using Bonferroni’s correction for multiple comparisons.
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Whereas this study must be viewed as preliminary because of
the limited number of patients and control subjects, the di¡er-
ences observed in NEP enzymatic activity and immunostaining
were very large and uniformly observed in all patients. Addition-
ally, diabetic db/db mice show similarly large increases in cuta-
neous NEP enzymatic activity compared with nondiabetic
littermates (Spenny, 2002). We suggest that in diabetic patients
with peripheral neuropathy, the combination of decreased neuro-
peptides resulting from the loss of cutaneous innervation and the
increase in cutaneous NEP observed in this study leads to a loss of
the neuroin£ammatory signaling seen in normal wound healing.
We hypothesize that this loss of neuroin£ammatory signaling
contributes to the poor wound healing observed in diabetes and
that treatment may potentially be directed at correcting this de¢cit.
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